OPT (Opthea) Accounts Payable & Accrued Expense : $38.10 Mil (As of Jun. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Opthea Accounts Payable & Accrued Expense?

Opthea's quarterly accounts payable & accrued expense increased from Jun. 2023 ($17.89 Mil) to Dec. 2023 ($31.70 Mil) and increased from Dec. 2023 ($31.70 Mil) to Jun. 2024 ($38.10 Mil).

Opthea's annual accounts payable & accrued expense increased from Jun. 2022 ($11.45 Mil) to Jun. 2023 ($17.89 Mil) and increased from Jun. 2023 ($17.89 Mil) to Jun. 2024 ($38.10 Mil).

Opthea Accounts Payable & Accrued Expense Historical Data

The historical data trend for Opthea's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opthea Accounts Payable & Accrued Expense Chart

Opthea Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

4.05

2.50

11.45

17.89

38.10

Opthea Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															11.45	8.67	17.89	31.70	38.10

Opthea Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Opthea Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opthea Ltd (NAS:OPT) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

CKDXF:USA UKJ:Germany OPT:Australia

Address

650 Chapel Street, Level 4, Suite 0403, South Yarra, VIC, AUS, 3141

Website

https://www.opthea.com

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.